Navigation Links
Greenberg Traurig London Team Represents Long-time Client AstraZeneca AB in Two Divestment Agreements
Date:11/9/2018

The London office of global law firm Greenberg Traurig, LLP represented AstraZeneca AB on its agreement with Grünenthal to divest the European rights to Nexium for an upfront payment of USD700 million with further sales-related and milestone payments of up to USD90 million. Nexium (esomeprazole) is a proton pump inhibitor that decreases the amount of acid produced in the stomach. The law firm also represented AstraZeneca AB on its agreement with Grünenthal to divest the global rights to Vimovo in all markets excluding the US and Japan for an upfront payment of USD115 million and further payments up to another USD17 million. Vimovo combines the non-steroidal anti-inflammatory drug naproxen with esomeprazole, the active ingredient in Nexium, for patients a risk of developing ulcers.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Grünenthal is a science-based pharmaceutical company specialised in innovative pain management and related therapies. These divestments are part of several transactions in which Greenberg Traurig’s London office has represented AstraZeneca over the past eight years.

The deal was led by Adam McArthur and Warren Brown, in-house lawyers at AstraZeneca AB. Greenberg Traurig team members involved in these latest transactions included: Paul Maher, Vice Chair of Greenberg Traurig; Fiona Adams, Co-Managing Shareholder of the London office and the Co-Chair of the firm’s Global Corporate Practice; shareholders Henrietta Walker and Sarah Moyles; associates David Hirschman, Charlotte Irvine, Miles Daly, Eleni Pittas, and Declan Grady; and IP Consultant Ewen Mitchell.

“It has been an absolute pleasure to represent AstraZeneca and to work with Adam and Warren, its dynamic and commercially driven legal team,” Maher said. “We are proud to have been able to help them achieve AstraZeneca’s strategic divestment goals.”

About Greenberg Traurig’s Corporate Practice
Greenberg Traurig’s Corporate Practice comprises more than 450 lawyers in the United States, Europe, Asia, the Middle East and Latin America who regularly advise public and privately held companies, entrepreneurs and investment funds on global mergers and acquisitions, corporate restructurings, private equity and venture capital, underwritten and syndicated offerings, commercial finance and syndicated lending, cross-border transactions, and general corporate matters. The group’s industry experience includes transactions in a wide range of fields, from the pharmaceutical, medical devices, and life sciences fields, to representations involving clients in the aviation, banking, consumer products, energy, food and beverage, health care, manufacturing, media, technology, and telecommunications sectors.

About Greenberg Traurig’s London Office: Greenberg Traurig, LLP in London has established itself as a multidisciplinary law firm, with more than 80 lawyers and growing. The London office provides partner-led advice to domestic and international clients on a range of matters across the legal spectrum. Lawyers at Greenberg Traurig in London advise U.K. and multinational clients operating in many different sectors, including chemicals, pharmaceuticals, life sciences, energy, real estate, financial services, automotive, retail, and communications.

About Greenberg Traurig: Greenberg Traurig, LLP (GT) has more than 2,000 attorneys in 38 offices in the United States, Latin America, Europe, Asia, and the Middle East. GT has been recognized for its philanthropic giving, was named the largest firm in the U.S. by Law360 in 2017, and is among the Top 20 on the 2018 Am Law Global 100. Web: http://www.gtlaw.com; Twitter: @GT_Law.

Read the full story at https://www.prweb.com/releases/greenberg_traurig_london_team_represents_long_time_client_astrazeneca_ab_in_two_divestment_agreements/prweb15906696.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related medicine technology :

1. Archbishop Desmond Tutu Advocates St John International Charity Work on Packed London Visit and Audience with HM The Queen
2. UKs Flagship Health & Safety Event Has Successful Inaugural Year in London
3. genae Opens Offices in London
4. FDNA Partners with London Medical Databases (LMD) to Provide Long-Awaited Online Access to Leading Dysmorphology Database
5. Klinische Studie von LKC Technologies bestätigt kosteneffektive Alternative zum Goldstandard beim Screening auf diabetische Retinopathie. Einzelheiten werden beim EURETINA/ESCRS in London bekanntgegeben
6. NW BIO CEO TO PRESENT AT SMis 3rd ANNUAL CANCER VACCINES CONFERENCE IN LONDON
7. FDNA to Exhibit at ASHG2014 Presenting Face2Gene Integrated With London Medical Databases (LMD) Online
8. FDNA exposera sa solution Face2Gene intégrée en ligne avec London Medical Databases (LMD) à lASHG 2014
9. Process Validation in the US and EU (Workshop, London)
10. New Cancer Center at Guys Hospital in London to be Equipped with Varian TrueBeam Treatment Machines
11. TapImmune Appoints David Laskow-Pooley, CEO of London Pharma, to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2019)... ... October 18, 2019 , ... Beginnings Treatment Centers, a ... as the official sponsor of the Alcohol and Other Drug Awareness Week ... students to make informed decisions around alcohol and other drugs through individual education and ...
(Date:10/17/2019)... (PRWEB) , ... October 17, 2019 , ... ... patients with neuroblastoma, a deadly pediatric nerve cancer, who would otherwise have no ... , Neuroblastoma is one of the most common and aggressive pediatric nervous system ...
(Date:10/15/2019)... ... October 14, 2019 , ... ... linearity and calibration verification kit, for Roche cobas® analyzers, Order No. 507ro. ... B (Apo-B). Each VALIDATE® LP2 kit, liquid, ready-to-use, and prepared using ...
Breaking Medicine Technology:
(Date:10/17/2019)... ... ... Whole Foods Market, along with Austin leaders, has joined forces with Blue Zones ... assessment by the Blue Zones team of the Austin Metro area and population that ... work, grow up, and grow old. , Blue Zones is based on research and ...
(Date:10/15/2019)... , ... October 15, 2019 , ... ... FDA’s Most Recent IFU Guidance , **An FDAnews Webinar**, Tuesday, October 29, 2019, ... for Use (IFU) guidance have on new drug applications and biologics license applications? ...
(Date:10/15/2019)... (PRWEB) , ... October 15, 2019 , ... Nashville Fertility ... be the latest fertility doctor to join the practice. In addition to treating general ... syndrome (PCOS). , The team at NFC looks forward to Dr. Van Heertum joining ...
(Date:10/11/2019)... ... ... A Topping Out event was hosted today at the construction site of the ... The event celebrated reaching the final height of the structure set to open in ... kind in Texas, STA’s facility will be home to an organ recovery center including ...
(Date:10/10/2019)... ... 10, 2019 , ... Caring.com, a leading senior care referral service with Family ... for Seniors to Live. All 50 states and 302 cities in the U.S. were ... development. , According to the U.S. Census Bureau , almost 20 million ...
Breaking Medicine News(10 mins):